Myriad Genetics (MYGN) FY Conference June 11, 2025 02:00 PM ET Speaker0 All right. Good afternoon, everyone. My name is Matt Sykes, the Life Science Tools and Diagnostics Analyst at Goldman Sachs, and I have the pleasure of welcoming Myriad Genetics to our conference this afternoon, Sam Raha, President and CEO and Scott Loeffler, CFO. Sam, Scott, thanks for joining me. Pleasure to be here. Thanks for having us. Speaker1 Thanks for having us, Matt. Speaker0 Great. Maybe, Sam, if we just start off at a high l ...

MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via ultra-sensitive MRDSALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a collaboration with the National Can ...

Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaboratorsSALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share data from seven new research studies at the 2025 ASCO Annual Meeting, including MRD clinical outcome data from the MONSTAR-SCREEN-3 study. Myriad will also highlight how its comprehensive portfolio of ...